Muscle-invasive bladder cancer is lethal. Unfortunately, approximately 30% of bladder cancers have invaded muscle by the time of diagnosis[@b1]. According to statistical data from the American Cancer Society[@b2], there would be 73,510 new bladder cancer cases and 14,880 deaths due to bladder cancer in 2012 in the United States. In China, bladder cancer is one of the most common urinary malignancies and the eighth most common malignancy among males[@b3]. The most effective treatment for muscle-invasive bladder cancer is radical cystectomy combined with pelvic lymph node dissection. Studies in Western countries have reported 5-year survival rates of 54.5%--68%[@b4],[@b5] in bladder cancer patients who underwent radical cystectomy. However, few large scale studies have reported the oncologic outcome of radical cystectomy for treating bladder cancer in China; hence, we lack long-term prognostic information. This makes it difficult to assess prognosis and deliver preoperative patient education. Here, we report the survival details of a group of 271 Chinese bladder cancer patients who underwent radical cystectomy combined with pelvic lymph node dissection.

Patients and Methods {#s2}
====================

Patients {#s2a}
--------

A total of 271 patients (239 males and 32 females) with a median age of 60 years (range, 35--89 years) were enrolled in this study. All were preoperatively diagnosed with muscle-invasive bladder cancer. Radical cystectomy with pelvic lymph node dissection was performed as described previously[@b6]. Eleven patients received neoadjuvant chemotherapy and 47 patients received adjuvant chemotherapy. Five patients underwent radiation therapy. TNM staging was performed according to the system outlined by the American Joint Committee on Cancer (2002)[@b7]. Tumor grade was classified according to the 2004 World Health Organization classification[@b8].

Follow-up {#s2b}
---------

All patients were followed at 3-month intervals during the first 2 years after surgery and at 6-month intervals thereafter. Follow-ups comprised physical examination, blood chemistry analysis, and functional evaluation. Chest radiography and abdominal ultrasonography were performed every half a year. The first follow-up abdominal computed tomography (CT) examination was performed 3 months after surgery and once per year thereafter. A complete check-up was performed in patients with any evidence of recurrence or metastasis. Tumor recurrence, including local relapse and distant metastasis, was confirmed by CT or magnetic resonance imaging.

Statistical analysis {#s2c}
--------------------

The primary end point of the study was cancer-specific survival (CSS), which was calculated from the date of surgery to the date of death or last follow-up. Recurrence-free survival (RFS) was calculated from the date of surgery to the date of tumor recurrence. Overall survival (OS) was calculated from the date of surgery to the date of death. Survival curves were determined using the Kaplan-Meier method and compared using the log-rank test. Thirty-day mortality means any death happened within 30 days after radical cystectomy. All *P* values were two-tailed and *P* \< 0.05 was considered significant. Data were analyzed using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA).

Results {#s3}
=======

Clinicopathologic data {#s3a}
----------------------

Detailed clinicopathologic data are listed in [**Table 1**](#cjc-33-03-165-t01){ref-type="table"}. In this patient cohort, 107 (39.5%) had recurrent tumor before radical cystectomy. Regarding the type of urinary diversion used, conduit and neobladder accounted for 43.2% and 55.7% of procedures, respectively. Only 3 patients received other types of urinary diversion (continent cutaneous pouch or cutaneous ureterostomy). The median operation time was 325 min, and the median estimated blood loss was 500 mL, with a transfusion rate of 56.5%. Seven (2.6%) patients needed re-operation for severe complications, and there were 4 (1.4%) deaths in the first 30 days after surgery. Pathology showed that most patients had high grade urothelial cancer. Of the 271 patients, 212 (78.2%) had tumor confined to the bladder, whereas 59 (21.8%) had extravesical disease; 233 (86.0%) had negative lymph nodes, whereas 38 (14.0%) had local lymph node metastasis.

###### Clinicalpathologic features, intraoperative data, and hospitalization duration of 271 patients with bladder cancer

  Characteristic                                            No. of cases (%)
  -------------------------------------------------------- ------------------
  Median age^a^ (years)                                       60 (53, 69)
  Male patients                                                239 (88.2)
  Recurrent tumor                                              107 (39.5)
  Tumor multiplicity                                           162 (59.8)
  Gross hematuria                                              204 (75.3)
  Urinary irritation symptoms                                  75 (27.7)
  Smoking history                                              150 (55.4)
  Histologic subtype                                       
   Urothelial carcinoma                                        237 (87.5)
   Nonurothelial carcinoma                                     34 (12.5)
  Grade                                                    
   High                                                        180 (75.9)
   Low                                                         57 (24.1)
  T category                                               
   pTa-T1                                                      78 (28.8)
   pT2a                                                        67 (24.7)
   pT2b                                                        30 (11.1)
   pT3a                                                        36 (13.3)
   pT3b                                                        27 (10.0)
   pT4                                                         31 (12.1)
  N category                                               
   N^−^                                                        233 (86.0)
   N^+^                                                        38 (14.0)
  Organ-confined disease                                       212 (78.2)
  Form of urinary diversion                                
   Conduit                                                     117 (43.2)
   Neobladder                                                  151 (55.7)
   Others                                                       3 (1.1)
  Median operation time^a^ (min)                             325 (275, 380)
  Median length of postoperative hospital stay^a^ (days)      17 (13, 23)
  Reoperation                                                   7 (2.6)
  Deaths within 30 days after surgery                           4 (1.4)
  Median estimated blood loss^a^ (mL)                        500 (400, 800)
  Transfusion required                                         153 (56.5)
  Cancer recurrence                                            82 (30.3)
  Cancer death                                                 55 (20.3)
  Death for any reason                                         68 (25.1)

^a^These data are presented as median with interquartile range in parentheses.

Prognosis {#s3b}
---------

Median follow-up time was 31.7 months (range, 0.2--139.1 months). During follow-up, 82 patients developed recurrence and 55 died from bladder cancer. Detailed 5-year CSS data are listed in [**Table 2**](#cjc-33-03-165-t02){ref-type="table"}. The 5-year RFS, CSS, and OS rates were 61.6%, 72.9%, and 68.0%, respectively ([**Figure 1**](#cjc-33-03-165-g001){ref-type="fig"}). The 5-year CSS rate in patients with T1--T4 disease was 90.7%, 85.0%, 51.0%, and 18.0%, respectively ([**Figure 2A**](#cjc-33-03-165-g002){ref-type="fig"}). Patients with organ-confined disease had higher 5-year CSS rate than those with extravesical disease ([**Figure 2B**](#cjc-33-03-165-g002){ref-type="fig"}, 81.4% vs. 34.9%, *P* \< 0.001). Thirty-eight patients (14%) had lymph node tumor involvement; the 5-year CSS rate in these patients was 27.7%, which was significantly lower than that in patients without lymph node metastasis ([**Figure 2C**](#cjc-33-03-165-g002){ref-type="fig"}, *P* \< 0.001). Regarding histologic subtype, patients with urothelial carcinoma (UC) had a better prognosis than those with non-UC ([**Figure 2D**](#cjc-33-03-165-g002){ref-type="fig"}, 5-year CSS rate, 75.4% vs. 56.3%; *P* = 0.042). The 5-year CSS rate was much higher in patients with low grade UC than in those with high grade UC ([**Figure 2E**](#cjc-33-03-165-g002){ref-type="fig"}, 98.1% vs. 68.1%, *P* \< 0.001).

Univariate and multivariate analysis {#s3c}
------------------------------------

To find independent predictors for CSS, we performed Cox regression analysis. Univariate analysis showed that patient age, T category, N category, and histologic subtype were significant predictors for survival ([**Table 3**](#cjc-33-03-165-t03){ref-type="table"}). In multivariate analysis, patient age (hazard ratio, 2.045; *P* = 0.013) and T category (hazard ratio, 2.213; *P* \< 0.001) were independent predictors for CSS in the whole group ([**Table 3**](#cjc-33-03-165-t03){ref-type="table"}). However, in the cohort of patients with urothelial carcinoma, T category (hazard ratio, 1.889; *P* = 0.001) and tumor grade (hazard ratio, 8.563; *P* = 0.038) were independent predictors for CSS.

![Recurrence-free, cancer-specific, and overall survival curves for the patient cohort.\
A, 5-year recurrence-free survival rate is 61.6%. B, 5-year cancer-specific survival rate is 72.9%. C, 5-year overall survival rate is 68.0%.](cjc-33-03-165-g001){#cjc-33-03-165-g001}

###### Recurrence-free, cancer-specific, and overall survival after radical cystectomy

  Characteristic        No. of cases   5-year survival rate                                      
  -------------------- -------------- ---------------------- --------- ------- --------- ------- ---------
  T category                                                  \<0.001           \<0.001           \<0.001
   Ta-T1                     78               79.5%                     90.7%             84.5%  
   T2                        97               73.7%                     85.0%             81.0%  
   T3                        63               33.4%                     51.0%             49.1%  
   T4                        33               34.2%                     18.0%             10.9%  
  Depth of invasion                                           \<0.001           \<0.001           \<0.001
   Organ-confined           212               70.4%                     81.4%             77.3%  
   Extravesical              59               26.7%                     34.9%             27.7%  
  N category                                                  \<0.001           \<0.001           \<0.001
   N^−^                     233               66.7%                     77.2%             72.4%  
   N^+^                      38              18.2%^a^                   27.7%             24.9%  
  Histologic subtype                                           0.001             0.042             0.043
   UC                       237               65.3%                     75.4%             70.4%  
   Non-UC                    34               37.7%                     56.3%             52.3%  
   Total group              271               61.6%                     72.9%             68.0%  
  Tumor grade                                                  0.003            \<0.001            0.002
   Low grade                 57               83.1%                     98.1%             90.0%  
   High grade               180               59.5%                     68.1%             64.1%  

UC, urothelial carcinoma; Non-UC, non-urothelial carcinoma. ^a^ This is 4-year recurrence-free survival rate.

![Cancer-specific survival (CSS) curves for subgroups.\
A, the 5-year CSS rates in patients with T1--T4 disease are 90.7%, 85.0%, 51.0%, and 18.0%, respectively (*P* \< 0.001). B, patients with disease confined to the bladder had a cumulative 5-year CSS rate of 81.4%, compared with 34.9% for those with extravesical disease (*P* \< 0.001). C, CSS curves according to lymph nodes status. N^+^, patients with lymph node metastasis; N^−^, patients without lymph node metastasis. D, CSS curves according to histological subtype. UC, patients with urothelial carcinoma; Non-UC, patients with non-urothelial carcinoma. E, among urothelial carcinoma patients, low grade cases had higher CSS rate than high grade cases (98.1% vs. 68.1%, *P* \< 0.001).](cjc-33-03-165-g002){#cjc-33-03-165-g002}

Discussion {#s4}
==========

In the present study, we reported a group of 271 patients who underwent radical cystectomies, with 5-year RFS, CSS, and OS rates of 61.6%, 72.9%, and 68.0%, respectively. On subgroup analysis, the 5-year CSS rates of patients with T1--T4 disease were 90.7%, 85.0%, 51.0%, and 18.0%, respectively. This study provides long-term prognostic information of a group of Chinese patients, who underwent radical cystectomy for bladder cancer. This makes it possible to assess prognosis and deliver preoperative patient education.

Radical cystectomy plus pelvic lymph node dissection is the gold standard treatment for muscle-invasive bladder cancer. However, the procedure is time consuming and physically demanding for surgeons; hence, few surgeons specialize in this operation. Furthermore, patients may refuse to undergo the procedure due to the high risk of intraoperative and postoperative complications. For these reasons, there have been few large scale studies focusing on the long-term oncologic outcome of bladder cancer patients who underwent radical cystectomy. In China, there are even fewer of these studies. In 2002, Sun *et al*.[@b9] reported 196 radical cystectomies. With a median follow-up of 6.6 years in 135 patients, the reported 5-year survival rate was 66.2%. However, the statistical method used in this study was not standardized. In 2008, Niu *et al*.[@b10] reported the outcome of 356 radical cystectomies at Chinese institutes. The 5-year disease-free survival rate was 48%, 73%, 44%, 22%, and 0% for the whole group and patients with T2a, T2b, T3 and T4 disease, respectively. However, these data were collected from three centers, and the procedure and extent of surgery may have differed between them. Hence, the 5-year disease-free survival rate was not high (48%) in this cohort. Recently, Xu *et al*.[@b11] reported their experience with laparoscopic radical cystectomy. The oncologic outcome was satisfactory, with a 5-year CSS rate of 83.3%. However, most of the patients in this study (81%) had early stage (T2 or T1) disease, which may have contributed to the high survival rate. Huang *et al*.[@b12] provided the most detailed information on oncologic outcome, reporting estimated 5-year OS, CSS, and RFS rates of 73.7%, 81.3%, and 72.6%, respectively, in a group of 171 patients who underwent laparoscopic radical cystectomies. However, the sample size was relatively small in this study. In the present study, the data came from a single center and included detailed follow-up. Thus, any differences in surgical procedure or extent were minimized, and the prognostic information can be considered accurate. Moreover, our results are comparable with those in the Western literature ([**Table 4**](#cjc-33-03-165-t04){ref-type="table"})[@b13]--[@b16]. In addition to the oncologic outcome, we investigated the intraoperative parameters and mortality of radical cystectomy. Mean operation time and estimated blood loss were 325 min and 500 mL, respectively. The re-operation rate and mortality were also acceptable at 2.6% and 1.4%, respectively. In summary, our study provides evidence that radical cystectomy is a safe and effective method for treating bladder cancer in Chinese patients.

Predictors of the survival of radical cystectomy patients differ between studies. For example, in a very large scale Egyptian study[@b17], the authors reported 2,720 cases of bladder cancer, 49.4% of which were squamous tumors and treated with radical cystectomy. They considered tumor stage, histologic grade, and lymph node status as independent variables affecting the probability of survival. In a Canadian study, the authors declared that pathologic T category greater than 2, positive lymph nodes, unknown lymph node status, lymphovascular invasion, and positive surgical margins were associated with decreased CSS, whereas a surgeon procedure volume of 5 to 9 per year was independently associated with improved CSS[@b18]. In the present study, patient age and T category were independent predictors for CSS, which is consistent with the results of previous reports[@b17]--[@b19]. Hence, in patients with poor prognostic factors, continued follow-up may be helpful in detecting tumor recurrence. Recently, scholars have developed nomograms combining prognostic information from clinicopathologic data and biomarkers to predict the prognosis of bladder cancer patients. These nomograms have been considered reasonable and accurate for such predictions[@b20],[@b21].

###### Univariate and multivariate analysis of prognostic parameters

  Variable                Univariate analysis   Multivariate analysis                                    
  ---------------------- --------------------- ----------------------- --------- ------- --------------- ---------
  The whole group                                                                                        
   Age                           1.941              1.131--3.332         0.016    2.045   1.163--3.593     0.013
   T category                    2.274              1.715--3.015        \<0.001   2.213   1.612--3.037    \<0.001
   N category                    3.137              1.646--5.981         0.001    1.809   0.901--3.632     0.095
   Histologic subtype            1.961              1.012--3.800         0.046    1.483   0.718--3.063     0.287
  Urothelial carcinoma                                                                                   
   Age                           1.641              0.903--2.982         0.104    1.512   0.820--2.786     0.185
   T category                    2.301              1.688--3.137        \<0.001   1.889   1.314--2.714     0.001
   N category                    3.880              1.900--7.925        \<0.001   2.021   0.940--4.347     0.072
   Grade                        15.326             2.110--111.339        0.007    8.563   1.124--65.242    0.038

HR, hazard ratio; CI, confidence interval.

###### The 5-year cancer-specific survival rate after radical cystectomy: a comparison of the present study and published Western reports

  Report/study                   No. of cases   5-year cancer-specific survival rate (%)                 
  ----------------------------- -------------- ------------------------------------------ ---- ---- ---- ----
  Shariat *et al*.[@b13]             888                           81                      72   44   28   35
  Hautmann *et al*.[@b14]            788                           90                      72   43   28   21
  Madersbacher *et al*.[@b15]        507                           76                      74   52   36   33
  Manoharan *et al*.[@b16]           432                           81                      70   44   16   29
  Present study                      271                           91                      85   51   18   28

There are limitations to this study. First, it was retrospective; hence, bias is present. Second, the sample size was not very large. A further cooperative study using nomograms to predict prognosis in multiple Chinese medical centers is ongoing.

Conclusions {#s5}
===========

Radical cystectomy is a safe and effective method for the treatment of bladder cancer in Chinese centers. The prognosis of this group of Chinese bladder cancer patients was satisfactory and comparable with that reported in Western countries. Old age and high T category were associated with a poor prognosis in bladder cancer patients who underwent radical cystectomy.
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